vimarsana.com

ப்ரொஃபெஸர் ராபர்ட் பிருதோம்மே இல் ப்ரிந்ஸ்டந் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Integral Molecular and Optimeos Partner to Deliver Long-acting Therapeutic Antibodies Using Nanoparticle Formulation Technology

Share this article Share this article PHILADELPHIA, Jan. 7, 2021 /PRNewswire/  Integral Molecular and Optimeos Life Sciences have partnered to develop antibody therapeutics using long-acting, sustained delivery formulations that will improve patient care and quality of life. The partnership will leverage Integral Molecular s industry-leading platform for antibody discovery and include novel targets in cancer and autoimmune diseases. The therapeutics developed using Optimeos inverse flash nanoprecipitation (iFNP) platform will reduce the frequency of antibody injections for patients. Frequent IV administration is burdensome for patients and can greatly hinder the widespread adoption of therapeutic antibodies in the clinic, said Benjamin Doranz, PhD, President and CEO of Integral Molecular. Optimeos has solved this problem by encapsulating antibodies in nanoparticles to create long-acting, safe formulations which will improve many biotherapeutics on the market.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.